核衣壳蛋白 QIGYYRRATRRIRGG HLA-DRB1*11:01 IGYYRRATRRRGGD HLA-DRB1*11:01 GYYRRATRRRIGGDG HLA-DRB1*11:01 TPSTWLTYTGAIKL HLA-DRB1*07:01 DQIGYYRRATRRIRG HLA-DRB1*11:01 PQIAQFAPSASAFFG HLA-DRB1*09:01 WPQIAQFAPSASAFF HLA-DRB1*09:01 QIAQFAPSASAFFGM HLA-DRB1*09:01 IAQFAPSASAFFGMS HLA-DRB1*09:01 AALALLLLDRLNQLE HLA-DRB4*01:01,HLA-DPA1 03:01/DPB1*04, HLA-DRB3*01:0, HLA-DRB1*13:02, HLA-DRB1*11:0, HLA-DRB1*04:04, HLA-DRB1*01:01, HLA-DRB1*04, HLA-DPA1*02:01/DPB1*01:01, HLA-DPA1*01:03/DPB1*02:01, HLA-DRB1*04:05, HLA-DRB1*03:01, HLA-DRB1*08:02, HLA-DRB1*15:01, HLA DQA1*01:01/DQB1*05:01 ALALLLLDRLNQLES HLA-DRB4*01:01, HLA-DPA1*03:01/DPB1*04:02, HLA-DRB3*01:01、HLA-DRB1*13:02、HLA-DRB1*11:01、HLA-DRB1*04:04、HLA-DRB1*04:01、HLA-DRB1*01:01、HLA-DRB1*03:01、HLA-DRB1*04:05、HLA-DPA1*02:01/DPB1*01:01、HLA-DPA1*01:03/DPB1*02:01、HLA-DRB1*08:02、HLA-DRB1*15:01、HLA-DQA1*01:01/DQB1*05:01 PRWYFYYLGTGPEAG HLA-DRB1*07:01 RWYFYYLGTGPEAGL HLA-DRB1*01:01尖峰糖蛋白 AAEIRASANLAATKM HLA-DQA1*05:01/DQB1*03:01 NAQALNTLVKQLSSN HLA-DRB1*11:01 EVFNATRFASVYAWN HLA-DPB1*02:01、HLA DPB1*04:02、HLA-DPB1*05:01、 HLA-DQA1*01:02、HLA-DQA1*05:01、HLA-DQB1*03:01、HLA-DQB1*06:02、HLA-DRB1*01:01、HLA-DRB1*04:04、HLA-DRB1*04:05、HLA-DRB1*07:01、 HLA-DRB1*08:02、HLA-DRB1*09:01、 HLA-DRB1*11:01, HLA-DRB1*15:01, HLA-DPA1*03:01, HLA-DPB1*01:01, HLA-DPA1*01:03, HLA-DPA1*02:01 VFRSSVLHSTQDLFL HLA-DRB1*07:01, HLA-DRB1*01:01, HLA-DRB1*09:01, HLA-DRB1*04:05, HLA-DRB1*04:01, HLA-DRB1*03:01, HLA-DQA1*01:02/DQB1*06:02, HLA-DPA1*03:01/DPB1*04:02, HLA-DRB1*13:02, HLA-DPA1*02:01/DPB1*01:01、HLA-DRB4*01:01、HLA-DQA1*05:01/DQB1*02:01、HLA-DRB1*04:04、HLA- DPA1*01:03/DPB1*02:01、HLA-DQA1*05:01/DQB1*03:01 等位基因 HLA-DRB3*01:01、HLA-DRB4*01:01、HLA-DRB5*01:01 不可用,因此未将其纳入计算。
MOLECULAR TYPING 210075 HLA-A, B, C, DRB1,3,4,5, DQB1, DQA1, DPA1, (Intermediate resolution) 220064 HLA-B*5701 211016 HLA-A (Intermediate resolution) 210025 Narcolepsy – HLA-DRB1, DQB1 typing 211017 HLA-B (Intermediate resolution) 220078 HLA-B*5801 211018 HLA-C (Intermediate resolution) 240057 KIR Genotype 200002 HLA-DPA1, DPB1 (Intermediate resolution) 250055 MICA Genotype 200003 HLA-DQA1, DQB1 (Intermediate resolution) 220024 HLA-A2 Subtyping DNA (High Resolution) 210012 HLA-DRB1,3,4,5(中级分辨率)220019 HLA-DRB1(高分辨率)920001 HLA I类和II类高分辨率由NGS造血干细胞移植
目标:包容体肌炎(IBM)是老年人的进行性炎症性肌肉疾病,一些患者产生抗胞质5' - 核苷酸酶1A(NT5C1A,又名CN1A)抗体。人类白细胞抗原(HLA)是发展IBM的最高遗传危险因素。在这项研究中,我们旨在进一步定义HLA等位基因对IBM的贡献和抗CN1A抗体的产生。方法:我们使用Illumina下一代测序进行了113名高加索IBM患者的西澳大利亚人队列和112个种族匹配的对照。使用Genentech/Midas生物信息学包装进行等位基因频率分析和氨基酸对齐。等位基因频率。使用GGSTATSPLOT软件包进行了发作分析时的年龄。所有分析均在RSTUDIO版本1.4.1717中进行。结果:我们的发现验证了HLA-DRB1*03:01:01与IBM的独立关联,并将风险归因于DRβ1蛋白中位置74中的精氨酸残基。相反,DRB4*01:01:01和DQA1*01:02:01具有保护作用;不具备这些等位基因的DRB1*03:01:01的载体增加了IBM在普通高加索人群中发展的14倍。此外,上述基因型的患者平均比没有患者的患者早五年更早出现症状。我们没有发现与抗CN1A抗体产生的HLA关联。结论:高分辨率HLA测序更精确地表征了与IBM相关的等位基因,并定义了与早期疾病发作相关的单倍型。通过对免疫遗传学数据的高级生物统计分析来识别关键氨基酸残基,提供了机械洞察力和未来的方向,以发现IBM AetioPADENESECHESED。
